Production, characterisation, and in vitro nebulisation performance of budesonide-loaded PLA nanoparticles

References

• Ali HSM, York P, Amani A, Blagden N. Evaluation of a nanosuspension formulation prepared through microfluidic reactors for pulmonary delivery of budesonide using nebulizers. Iran J Pharm Res, 2014, accepted for publication
   Google Scholar
• Almeziny M, Clark B. High performance liquid chromatography assay method for simultaneous quantitation of formoterol and the two epimers of budesonide. J Pharm Pharmacol, 2007;59:74
   Google Scholar
• Amani A, Amini MA, Ali HSM, York P. Alternatives to conventional suspensions for pulmonary drug delivery by nebulisers: A review. J Pharm Sci, 2011;100(11):4563–70
   PubMedGoogle Scholar
• Amani A, Chrystyn H, Clark BJ, Abdelrahim ME, York P. Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers. J Pharm Pharmacol, 2009;61(12):1625–30
   PubMedGoogle Scholar
• Amani A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS Pharm Sci Tech, 2010;1–5
   PubMedGoogle Scholar
• Amini MA, Faramarzi MA, Mohammadyani D, Esmaeilzadeh-Gharehdaghi E, Amani A. Modeling the parameters involved in preparation of PLA nanoparticles carrying hydrophobic drug molecules using Artificial Neural Networks. J Pharm Innov, 2013;8:111–20
   Google Scholar
• Arya V, Coowanitwong I, Brugos B, Kim WS, Singh R, Hochhaus G. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. J Drug Target, 2006;14(10):680–6
   PubMed Web of Science ®Google Scholar
• Bai F, Yang X, Li R, Huang B, Huang W. Monodisperse hydrophilic polymer microspheres having carboxylic acid groups prepared by distillation precipitation polymerization. Polymer, 2006;47(16):5775–84
   Google Scholar
• Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol, 2001;425(2):109–16
   PubMed Web of Science ®Google Scholar
• Bennett WD, Zeman KL, Kang CW, Schechter MS. Extrathoracic deposition of inhaled, coarse particles (4.5 um) in children vs adults. Ann Occup Hyg, 1997;41(inhaled particles VIII):497–502
   Google Scholar
• Berg EB, Picard RJ. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Resp Care, 2009;54(12):1671–8
   PubMed Web of Science ®Google Scholar
• Berlinski A, Waldrep JC. Aerosol characterization of nebulized intranasal glucocorticoid formulations. J Aerosol Med, 2001;14(2):237–44
   PubMedGoogle Scholar
• Bodmeier R, Maincent P. 1998. Polymeric dispersions as drug carriers. New York: Marcel Dekker
   Google Scholar
• Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci, 1986;75(5):433–8
   PubMed Web of Science ®Google Scholar
• Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetics. J Control Release, 2002;83(3):389–400
   PubMed Web of Science ®Google Scholar
• Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy, 1999;54(7):691–9
   PubMedGoogle Scholar
• FDA. 2008. US Food and Drug Administration. Inactive ingredient search for approved drug products
   Google Scholar
• Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm, 1989;55(1):R1–4
   Web of Science ®Google Scholar
• Garti N. A new approach to improved stability and controlled release in double emulsions, by the use of graft-comb polymeric amphiphiles. Acta Polym, 1998;49(10–11):606–16
   Google Scholar
• Gorner T, Gref R, Michenot D, Sommer F, Tran MN, Dellacherie E. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J Control Release, 1999;57(3):259–68
   PubMed Web of Science ®Google Scholar
• Hamoudeh M, Faraj AA, Canet-Soulas E, Bessueille F, Leonard D, Fessi H. Elaboration of PLLA-based superparamagnetic nanoparticles: Characterization, magnetic behaviour study and in vitro relaxivity evaluation. Int J Pharm, 2007;338(1–2):248–57
   PubMedGoogle Scholar
• Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm, 2005;299(1):167–77
   PubMedGoogle Scholar
• Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y. Treatment of experimental arthritis with poly (d, l-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis, 2005;64(8):1132–6
   PubMed Web of Science ®Google Scholar
• Holt J. MMAD calculator. Avilable at: http://www.mmadcalculator.com. Accessed 15 May 2012.
   Google Scholar
• Hyvonen S, Peltonen L, Karjalainen M, Hirvonen J. Effect of nanoprecipitation on the physicochemical properties of low molecular weight poly (l-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone dipropionate. Int J Pharm, 2005;295(1):269–81
   PubMedGoogle Scholar
• Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res, 2002;19(2):189–94
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 2007;59(7):631–44
   PubMed Web of Science ®Google Scholar
• Knoch M, Keller M. The customised electronic nebuliser: A new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv, 2005;2(2):377–90
   PubMedGoogle Scholar
• Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol, 2004;44(1):67–72
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol, 2009;260(1):33–8
   PubMed Web of Science ®Google Scholar
• Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med, 1999;12(2):47–53
   PubMedGoogle Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 2004;56(7):827–40
   PubMed Web of Science ®Google Scholar
• Pedersen S. Choice of inhalation therapy in paediatrics. Eur Respir Rev, 1994;4(18):85–8
   Google Scholar
• Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YTF. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: Physicochemical characterization and in vitro, in vivo evaluations. Int J Nanomed, 2011;6:2351–66
   PubMed Web of Science ®Google Scholar
• Shen Y, Longo ML, Powell RL. Stability and rheological behavior of concentrated monodisperse food emulsifier coated microbubble suspensions. J Colloid Interface Sci, 2008;327(1):204–10
   PubMedGoogle Scholar
• Shrewsbury SB, Bosco AP, Uster PS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm, 2009;365(1–2):12–17
   PubMedGoogle Scholar
• Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol, 2007;25(12):563–70
   PubMed Web of Science ®Google Scholar
• Tajber L, Corrigan DO, Corrigan OI, Healy AM. Spray drying of budesonide, formoterol fumarate and their composites-I. Physicochemical characterisation. Int J Pharm, 2009;367(1 and 2):79–85
   PubMedGoogle Scholar
• Tam JM, McConville JT, Williams Iii RO, Johnston KP. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci, 2008;97(11):4915–33
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of Î22-agonist particle size. J Biomed Mater Res B: Appl Biomater, 2005;172(12):1497–504
   Google Scholar
• Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res, 2002;19(10):1564–71
   PubMedGoogle Scholar
• Wang Z, Deng Y, Sun S, Zhang X. Preparation of hydrophobic drugs cyclodextrin complex by lyophilization monophase solution. Drug Dev Ind Pharm, 2006;32(1):73–83
   PubMed Web of Science ®Google Scholar
• Yang S, Wu ZH, Yang W, Yang MB. Thermal and mechanical properties of chemical crosslinked polylactide (PLA). Polym Test, 2008;27(8):957–63
   Google Scholar
• Zweers MLT, Grijpma DW, Engbers GHM, Feijen J. The preparation of monodisperse biodegradable polyester nanoparticles with a controlled size. J Biomed Mater Res B: Appl Biomater, 2003;66(2):559–66
   PubMed Web of Science ®Google Scholar